IP Library Granted Patent US 7,488,487
Granted Patent B2
US 7,488,487 · App. 10/660,194 · Granted Feb 10, 2009

Methods of inducing immune responses through the administration of auxtrophic attenuated dal/dat double mutant Listeria strains

Assignee: The Trustees of the University of Pennsylvania
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,488,487
App. No.
10/660,194
Granted
Feb 10, 2009
Kind
B2
Abstract

The present invention includes a method of eliciting a T-cell immune response to an antigen in mammal. The method of eliciting a T-cell immune response includes administering mammal an auxotrophic attenuated strain of listeria which expresses the antigen. The auxotrophic attenuated strain of listeria includes a mutation in at least one gene whose protein product is essential for growth of bacteria.

Claims (13)

1. A method of inducing an immune response against a cancer cell in a mammal, the method comprising administering to said mammal an auxotrophic attenuated strain of Listeria comprising an antigen expressed by said cancer cell, wherein said auxotrophic attenuated strain of Listeria comprises a mutation in both the dal and dat genes of Listeria .

2. The method of claim 1 , wherein said antigen is expressed from a vector.

3. The method of claim 1 , wherein said antigen is expressed from the Listeria genome.

4. The method of claim 1 , wherein said auxotrophic attenuated strain of Listeria is administered orally, parenterally, intranasally, intramuscularly, intravascularly, intravenously, intrarectally or intraperitoneally.

5. The method of claim 1 , wherein said cancer cell is a cervical cancer cell.

6. The method of claim 1 , wherein said Listeria is L. monocytogenes .

7. The method of claim 1 , wherein said cancer cell is a melanoma cancer cell, a breast cancer cell, or a leukemia cell.

8. The method of claim 5 , wherein said antigen is HPV E6 of IIPV E7.

9. The method of claim 1 , wherein said antigen is the bcr/abl antigen.

10. The method of claim 1 , wherein said antigen is MΛGE1 or MZ2-E.

11. The method of claim 1 , wherein said antigen is MVC-1 or IIER-2.

12. The method of claim 1 , wherein said antigen is expressed as a fusion protein with lysteriolysin O (LLO) or phosphatidylinositol-specific phospholipase (PI-PLC).

13. The method of claim 1 , wherein said antigen is expressed from a Listeria hly, p60,actΛ, plcA, mpl, plcB, or in1A gene promoter.

Continuity (4)
Continuation 1013625300 · May 1, 2002
Division 0952020700 · Mar 7, 2000
Division 0897290200 · Nov 18, 1997
Related Publication 20050048081A1 · Mar 3, 2005